Harmony Biosciences is trading at $37.50, up 4.08% in pre-market, with no reported catalyst explaining the move.
- Available reporting surfaced no new company announcement or court ruling explaining the October 23 move.
- The company’s investor-relations page lists November 4 for its next quarterly results.
- Prior-session weakness was linked to closing arguments in Wakix patent litigation; a court ruling remained pending, but that context does not establish the cause of this pre-market gain.